Company intelligence / Profile preview
7 Hills Pharma
Houston, Texas, United States
- Ownership
- Private
- Employees
- ~25
- Development stage
- Other
01
Overview
7 Hills Pharma's lead asset alintegimod is in Phase Ib/IIa clinical trials for solid tumors, showing promise for overcoming anti-PD-1 resistance. 7HP935 is in IND-enabling studies to augment cell and gene therapies for hematologic disorders. Additional preclinical programs include a DNA vaccine against Chagas disease.
- Therapeutic areas
- OncologyInfectious DiseasesHematology
- Modalities
- Small moleculeDNA vaccineProphylactic vaccine
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
National Institutes of Health (NIH)CPRIT (Cancer Prevention and Research Institute of Texas)
Beyond the preview
Go deeper on 7 Hills Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 7 Hills Pharma.